Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
MaxCyte, Inc. is a leading cell engineering company specializing in advanced platform technologies for cell and gene therapies. Its proprietary Flow Electroporation technology enables efficient delivery of molecules into cells, supporting biopharmaceutical companies and academic institutions. With a growing market opportunity in cell therapy, MaxCyte's ExPERT platform includes various instruments and disposables. Recent innovations include the acquisition of SeQure Dx, enhancing its service offerings in gene editing assessments.
This description was generated via AI from an annual report. Updated about 1 year ago.